Drugs

4 CGMP Issues at Integrity Partners Facility

A 6/16-6/24/2025 FDA inspection at the Integrity Partners Group’s Chemisphere drug manufacturing facility in St. Louis, MO, identified four current good manufacturing practice (CGMP) regulation violations in the firm’s production of finished drugs. A just-released 12/15/2025 Warning Letter says the specific violations were:

failure to have for each batch of drug product an appropriate laboratory determination of satisfactory conformance to final specifications for each drug product, including the identity and strength of each active ingredient, before release, and, for each batch of drug product required to be free of objectionable microorganisms, appropriate laboratory testing as necessary;
failure to conduct at least one test to verify the identity of each component of a drug product, and failure to validate and establish the reliability of a component supplier’s test analyses at appropriate intervals;
failure to establish and follow adequate written procedures for cleaning and maintenance of equipment; and
failure to establish written procedures for production and process control designed to assure that manufactured drug products have the identity, strength, quality, and purity they purport or are represented to possess.

FDA says the firm’s quality systems are inadequate and reminds Chemisphere that it is responsible for the quality of the drugs it produces as a contract facility, regardless of any agreements it has with product owners. The agency recommends that Chemisphere engage a qualified consultant to assist it in meeting CGMP requirements.

Integrity was told to address the Chemisphere problems promptly and to respond with a list of specific steps it has taken to address the problems and prevent their recurrence, with a schedule for completing the corrections.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome